MedTrace Logo

Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation

NCT06853886 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-05-20

No results posted yet for this study

Summary

Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.

Conditions

  • Chronic Hepatitis B Virus

Interventions

OTHER

blood sample HBV patient

During a boold sample at only one follow up visit: * 3 tubes EDTA 10 ml per patient * 1 tube "Paxgene" 1ml * 2 dry tube per patient

OTHER

blood sample healthy volunteers

* 3 tubes EDTA ideally age and sex matched to CHB patient. * 1 tube "Paxgene" 1ml * 2 dry tube

Sponsors & Collaborators

  • National Agency for Research on AIDS and Viral Hepatitis (ANRS)

    collaborator OTHER

  • University Hospital, Limoges

    lead OTHER

Principal Investigators

  • Paul CARRIER, MD · University Hospital, Limoges

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2028-10-01
Completion
2028-10-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06853886 on ClinicalTrials.gov